Antibodies and Antimatter: The Resurgence of Immuno-PET
Open Access
- 17 December 2008
- journal article
- review article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (1), 2-5
- https://doi.org/10.2967/jnumed.108.056887
Abstract
The completion of the human genome, coupled with parallel major research efforts in proteomics and systems biology, has led to a flood of information on the roles of individual genes and proteins in normal physiologic processes and their disruptions in disease. In practical terms, this information has opened the door to increasingly targeted therapies as specific molecular markers are identified and validated. The ongoing transition from empiric to molecular medicine has engendered a need for corresponding molecular diagnostics, including noninvasive molecular imaging. Convergence of knowledge regarding key biomarkers that define normal biologic processes and disease with protein and imaging technology makes this an opportune time to revisit the combination of antibodies and PET, or immuno-PET.Keywords
This publication has 21 references indexed in Scilit:
- Antibodies for Molecular Imaging of CancerThe Cancer Journal, 2008
- Immuno-PET: A Navigator in Monoclonal Antibody Development and ApplicationsThe Oncologist, 2007
- Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An UpdateClinical Cancer Research, 2007
- Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out viewNuclear Medicine and Biology, 2007
- Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer PatientsClinical Cancer Research, 2006
- Identification of a Novel Prostate Tumor Target, Mindin/RG-1, for Antibody-Based Radiotherapy of Prostate CancerCancer Research, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments forIn vivoImagingCancer Research, 2005
- Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 DiabodyCancer Research, 2005
- Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal CancerClinical Cancer Research, 2004